OLEPTRO (trazodone hydrochloride) by Mthera Pharma is trazodone’s antidepressant action is not fully understood, but is thought to be related to its enhancement of serotonergic activity in the cns. First approved in 2010.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
OLEPTRO is an extended-release oral tablet formulation of trazodone hydrochloride, a serotonergic antidepressant approved for major depressive disorder. The mechanism combines selective serotonin reuptake inhibition with 5HT2 receptor antagonism, though the precise contribution of each action to clinical efficacy remains incompletely understood. Trazodone is commonly used for both depression and off-label sleep disturbances.
Product approaching loss of exclusivity with limited commercial momentum; brand team will shift focus to defending against generics and optimizing niche positioning.
trazodone’s antidepressant action is not fully understood, but is thought to be related to its enhancement of serotonergic activity in the CNS. Trazodone is both a selective serotonin reuptake inhibitor (SSRI) and a 5HT2 receptor antagonist and the net result of this action on serotonergic…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
PK Study of Multi-dose Trazodone Hydrochloride Prolonged-released Tablets in Healthy Chinese
PK Study of Diet Effect of Trazodone Hydrochloride Prolonged-Released Tablets in Healthy Chinese
A Clinical Study of Trazodone Hydrochloride Prolonged-Release Tablets for Treatment of Depression
Worked on OLEPTRO at Mthera Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
LOE in ~3 years — strategic planning for patent cliff underway
Working on OLEPTRO offers exposure to mature-market brand management, competitive defense, and lifecycle optimization in psychiatry—valuable skills for antidepressant portfolio strategy. However, the approaching LOE and low current job posting volume signal limited near-term growth and potential team contraction; career advancement may require lateral moves to growth-stage products.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo